Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Why one gut microbe is attracting attention in heart failure research

27

Sep 2026

Why one gut microbe is attracting attention in heart failure research

Researchers found that chronic systolic heart failure caused by nonischemic cardiomyopathy was associated with reduced gut microbial diversity, depletion of Bifidobacterium, and lower microbial short-chain fatty acid production potential. Higher Bifidobacterium abundance and higher circulating indole-3-propionic acid levels were associated with milder disease and clinical improvement, although the findings do not establish causality.

Hypofractionated radiotherapy for prostate cancer matches conventional treatment outcomes

27

Sep 2026

Hypofractionated radiotherapy for prostate cancer matches conventional treatment outcomes

Men with high-risk prostate cancer have a higher likelihood of having residual disease following prostatectomy and may require radiation therapy after surgery, particularly when PSA levels begin to rise. Conventional postprostatectomy radiotherapy (COPORT) is typically delivered over 37 fractions, while hypofractionated postprostatectomy radiotherapy (HYPORT) delivers a slightly lower total radiation dose over just 25 fractions.

Gut bacteria signature may predict type 2 diabetes risk

27

Sep 2026

Gut bacteria signature may predict type 2 diabetes risk

Changes in the composition of bacteria in the gut could provide early warning of type 2 diabetes (T2D), new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) has found.

Could the Mediterranean diet protect the brain through the gut?

27

Sep 2026

Could the Mediterranean diet protect the brain through the gut?

A narrative review finds that the Mediterranean diet may support brain health through gut microbiome, immune, metabolic, and barrier-related pathways, but direct human evidence that microbiome remodeling mediates neuroprotection remains limited. The proposed mechanisms involve microbial metabolites, reduced inflammatory signaling, stronger intestinal and blood-brain barrier function, and possible effects on processes linked to Alzheimer’s and Parkinson’s diseases.

Heated tobacco users had more hypertension, but the story is not that simple

27

Sep 2026

Heated tobacco users had more hypertension, but the story is not that simple

A large Japanese real-world cohort study found that current heated tobacco product users had a higher risk of developing hypertension than never-smokers in the primary adjusted analysis. However, the association weakened in several sensitivity analyses, and the observational study could not separate the effects of current heated tobacco use from previous cigarette exposure.

Could age help explain why psychedelic studies reach different conclusions?

27

Sep 2026

Could age help explain why psychedelic studies reach different conclusions?

A cross-sectional study of 1,088 adults found that lifetime classic psychedelic use was associated with lower current anxiety and depression symptoms among younger adults, but these associations weakened with age. Mystical experiences may partly explain the age-related pattern, although the observational design cannot establish that psychedelic use caused the mental health differences.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.